LC-MS characterization of valsartan degradation products and comparison with LC-PDA

Authors

  • Sumaia Araújo Pires Federal University of Alfenas; Institute of Chemistry; Laboratory of Pharmaceutical Analysis and Characterization
  • Letícia Martins Mota Federal University of Alfenas; Institute of Chemistry; Laboratory of Pharmaceutical Analysis and Characterization
  • Jerusa Simone Garcia Federal University of Alfenas; Institute of Chemistry; Laboratory of Pharmaceutical Analysis and Characterization
  • Phellipe Honorio Amaral UNICAMP; Institute of Chemistry; Thomson Laboratory of Mass Spectrometry
  • Eduardo César Meurer UNICAMP; Institute of Chemistry; Thomson Laboratory of Mass Spectrometry
  • Marcos Nogueira Eberlin UNICAMP; Institute of Chemistry; Thomson Laboratory of Mass Spectrometry
  • Marcello Garcia Trevisan Federal University of Alfenas; Institute of Chemistry; Laboratory of Pharmaceutical Analysis and Characterization

DOI:

https://doi.org/10.1590/S1984-82502015000400010

Abstract

Valsartan was submitted to forced degradation under acid hydrolysis condition as prescribed by the ICH. Degraded sample aliquots were separated via HPLC using a Hypersil ODS (C18) column (250 x 4.6 mm i.d., 5 µm). Either photodiode array (PDA) detection or mass spectrometry (MS) full scan monitoring of HPLC runs were used. HPLC-PDA failed to indicate Valsartan degradation under forced acid degradation, showing an insignificant peak area variation and that Valsartan apparently remained pure. HPLC-MS using electrospray ionization (ESI) and total ionic current (TIC) monitoring did not reveal any peak variation either, but inspection of the ESI mass spectra showed the appearance of m/z 306 and m/z 352 ions for the same retention time as that of Valsartan (m/z 436). These ions were identified as being protonated molecules of two co-eluting degradation products formed by hydrolysis. These assignments were confirmed by ESI-MS/MS with direct infusion of the degraded samples. The results showed that the use of selective HPLC-MS is essential for monitoring Valsartan degradation. Efficient HPLC separation coupled to selective and structural diagnostic MS monitoring seems therefore mandatory for comprehensive drug degradation studies, particularly for new drugs and formulations, and for method development.

Downloads

Download data is not yet available.

Downloads

Published

2015-12-01

Issue

Section

Articles

How to Cite

LC-MS characterization of valsartan degradation products and comparison with LC-PDA . (2015). Brazilian Journal of Pharmaceutical Sciences, 51(4), 839-845. https://doi.org/10.1590/S1984-82502015000400010